Scott Gottlieb's Appoinment Could be Good for Valeant Trump's choice of Scott Gottlieb as head of FDA could be a net good for Valeant. Gottlieb's approach to lowering drug prices is reportedly making the approval process more efficient, thereby lowering the costs that drug makers need to recoup and speeding the entry of generics to market, through relaxation of regulations.
And according to Bloomberg, he has received speaking and / or consulting fees from Valeant.
https://www.bloomberg.com/politics/articles/2017-03-10/trump-s-leading-candidate-for-fda-is-said-to-be-scott-gottlieb